Ratings by RBC Capital
| Date | Analyst | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|---|
| 7/21/2026 | David Paige | Axon Enterprise | AXON | Maintain | Outperform (N/A) |
735.00 (N/A) |
|
Details | |
| 7/21/2026 | Brian Abrahams | Karyopharm Therapeutics | KPTI | Maintain | Outperform (N/A) |
16.00 (N/A) |
|
Details | |
 |
|||||||||
|
|||||||||
|
|||||||||
|
|||||||||
|
|||||||||
|
|||||||||
|
|||||||||
|
|||||||||
| 24,554 more... | |||||||||
